Skip to main content

Table 5 Logistic regression modeling triptan insufficient response with backward selection results. P-values in bold indicate statistically significant factors (N = 1033)

From: A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication

  Odds ratio estimates  
Factor Effect Point estimate 95% Wald confidence intervals p-value
Agea   0.999 0.988, 1.011 0.930
Sexa Female vs Male 0.920 0.663, 1.277 0.612
Currently taking OTC medications for migrainesa Yes vs No 1.465 1.000, 2.147 0.050
When do you usually take your prescribed acute medication?a After pain has started and I have an idea of how severe it is vs At first sign of a migraine (before pain starts) 2.433 1.258, 4.703 0.008
  When pain starts vs At first sign of a migraine (before pain starts) 1.726 1.252, 2.380 0.001
On average, per month over the last 3 months: No. of migraine-related headache daysb   0.926 0.856, 1.002 0.057
MSQ domain: Preventivea   0.980 0.968, 0.992 0.001
MSQ domain: Emotionala   0.981 0.970, 0.992 0.001
EQ-5D utility scoresa   0.106 0.032, 0.355 < 0.001
Total headache days (including migraine, tension, rebound, etc.) per month in last 3 monthsb   1.095 1.023, 1.174 0.010
How severe have the patient’s migraine attacks been over the last 3 months?b   1.025 1.003, 1.048 0.027
  1. aPatient reported. bPhysician reported
  2. The results in the table are from a backward logistic regression with a significance level of 0.1 for a variable to stay in the model. A total of 380 patients (380/1413; 26.8%) were excluded from the analyses due to missingness of variables
  3. EQ-5D = EuroQol 5-Dimensions questionnaire; MSQ = Migraine-Specific Quality of Life Questionnaire; OTC = over-the-counter